GlobeImmune Funding: How Much Did They Raise & Key Investors

How Much Did GlobeImmune Raise?
Funding & Key Investors

GlobeImmune, a specialized biopharmaceutical entity, has successfully secured a significant capital infusion, bringing its total funding to $15M. This latest financial milestone, characterized by a $15M strategic investment, underscores the market confidence in the company's proprietary Tarmogen platform. By leveraging this influx of resources, the organization is positioned to accelerate its clinical development programs, which are currently addressing critical unmet needs in oncology and infectious disease management.

The capital allocation reflects a robust commitment to advancing a diverse pipeline that spans Phase 2 clinical trials. As the company navigates the complexities of drug development, this recent financing serves as a vital catalyst for sustaining its research-heavy operational model and maintaining its competitive edge in the biotechnology sector.

What is GlobeImmune?

GlobeImmune

Manufacturing

Pharmaceuticals

Business Services

GlobeImmune, Inc. operates at the intersection of immunology and oncology, focusing on the development of therapeutic products designed to modulate the immune system. Central to its value proposition is the Tarmogen platform, a proprietary technology that utilizes yeast-based vectors to elicit targeted T-cell responses. The company's clinical portfolio is extensive, featuring candidates such as GS-4774 for hepatitis B and GI-6301 for brachyury-expressing cancers. By targeting specific protein expressions, GlobeImmune aims to provide precision therapies for patients with limited treatment options. Its market position is further bolstered by strategic collaborations with industry leaders like Gilead Sciences and Celgene, which validate the scientific rigor of its platform and provide essential infrastructure for large-scale clinical validation.

How much funding has GlobeImmune raised?

GlobeImmune has raised a total of $15M across 1 funding round:

2014

Stock Offering

$15M

Stock Issuance/Offering (2014): $15M, investors not publicly disclosed

Key Investors in GlobeImmune

Undisclosed Investor

Undisclosed investor participating in the funding round.

Undisclosed Investor

Undisclosed investor participating in the funding round.

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for GlobeImmune?

Looking ahead, GlobeImmune is poised to transition its lead candidates through the critical phases of clinical evaluation. The strategic deployment of the $15M will likely prioritize the advancement of GI-4000, currently in Phase 2b trials for resected pancreas cancer, and the expansion of its preclinical pipeline targeting tuberculosis and HIV. The company's ability to maintain its existing strategic partnerships will be paramount as it seeks to de-risk its development cycle and move toward potential commercialization. Investors and stakeholders will be closely monitoring the data readouts from its ongoing trials, as these results will serve as the primary indicators of the company's long-term viability and its potential to disrupt the current standard of care in immunotherapy.

See full GlobeImmune company page

See More Financial Insights